Pediatric Resource Center

Pediatric patients and their families probably didn’t see a diabetes diagnosis coming. They have to learn a lot quickly, and Tresiba® has guides and resources to help them.

Tresiba® is the only basal insulin indicated to improve glycemic control in children as young as 1 year of age with type 1 or type 2 diabetes, but it is not recommended for pediatric patients requiring less than 5 units of Tresiba®.1

Two girls and one boy

Support for families dealing with pediatric diabetes

Four kids in a row

Tresiba® Starter Brochure

For families who want to learn more about Tresiba® and pediatric patients

Mother and Child

Blood Sugar Diary

Give parents and pediatric patients a hand tracking their blood glucose

Group of five kids

Tresiba® Type 1 Caregivers Brochure

Help parents and their children adjust to a type 1 diagnosis

Find additional brochures for your pediatric patients with type 1 diabetes at NovoMedLink.com.

Conversations with caregivers and patients after a diabetes diagnosis

As a pediatric health care professional, you know the challenges facing families when a child has diabetes. Below are a few ways to address concerns patients and caregivers may have about pediatric diabetes and basal insulin therapy. Consider using these talking points as you navigate the tough conversations that follow a diabetes diagnosis.

FlexTouch® Needle

Injecting

Tresiba® uses NovoFine® Plus needles, which are the shortest and thinnest available from Novo Nordisk.
 

Addressing fears about needles:

  • Create a calm environment. Advise caregivers to find ways to keep things calm and positive. Maybe a favorite show or cartoon on a tablet can help.
  • Make it quick. Don't rush or seem anxious, and remember that slower is not better.

Diet

Patients and caregivers who sign up for Cornerstones4Care® have access to meal-planning tools and recipes.
 

Encouraging healthy eating:

  • Make it about balance. Suggest caregivers frame talks about diet in a way that allows for creativity and choice.
  • A family affair. Remind caregivers that eating balanced meals isn’t a punishment for children with diabetes, it’s something everyone should be doing. 
Green Person

Exercise

The Diabetes Health Coach offers extra diabetes management support for patients starting on Tresiba®.
 

Advocating for regular activity:

  • Get the kids out. Remind caregivers of their child’s natural inclination for exploration. Take them on a walk to a park or around the neighborhood. 
  • Encourage kids to play sports. Many park districts and schools offer sports programs. Just be sure to understand and educate others on the signs and symptoms of hypoglycemia and always carry a snack or glucose tablets in case the child's blood sugar gets too low.
Smiling Face

Forming Healthy Habits

The Tresiba® Blood Sugar Diary enables pediatric patients to track their progress.
 

Being a role model:

  • Build healthy habits together. Encourage parents to get involved in routines and to keep things positive. 
  • Reinforce good behavior. Advise parents and caretakers that a small reward or just simple recognition goes a long way.

Don't forget that Tresiba® offers helpful guides for you and your patient’s caregiver. Want help delivering the news of a diagnosis? This guide has tips. Looking for a guide to explaining injections to caregivers and young patients? Find out more about Tresiba® FlexTouch® in this guide and below.

Tresiba® FlexTouch® is a prefilled insulin pen with no push-button extension

Lantus® SoloStar® U-100 Pen

Hand Holding Injector Pen

Tresiba® FlexTouch® U-100

Hand holding FlexTouch®

No matter what dose is dialed, the Tresiba® FlexTouch® U‑100 push button doesn’t extend any higher.

Green check mark

Contains 300 total units


Green check mark

Maximum dose of 80 units in a single injection


Green check mark

1-unit dose increments


After opening, Tresiba® may be used for up to 8 weeks when kept at room temperature or in the refrigerator vs 4 weeks for insulin glargine U-100.1,2,a,b That’s 2x longer in-use time than insulin glargine U-100.

aOpened (in-use) Tresiba® should be refrigerated (36°F to 46°F [2°C to 8°C]) or kept at room temperature (below 86°F [30°C]), away from direct heat and light.1

bOpened (in-use) Lantus® SoloSTAR® device must be discarded 4 weeks after being opened. Once in use, the device must be kept at room temperature.2


Checkmark in circle

Covered on the majority of commercial plans nationwide3


Trusted partners

These organizations have teamed up with Novo Nordisk to help young patients with diabetes. If caregivers ask for trusted sites to learn more about diabetes in children, consider the following.


Dive deeper into Tresiba®



Novo Nordisk provides support for your patients with diabetes

See why Tresiba® may be an option for your pediatric patients with diabetes

Needles are sold separately and may require a presecription in some states. 

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.

 

References:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2016.
  2. Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; August 2015.
  3. Fingertip Formulary; June 2016.